Effectiveness of C5a aptamers in a TNBS‑induced colitis mouse model

Li,Zhiping; Wang,Xiwen; Chen,Man; Wang,Yuanyuan; Sun,Rui; Qu,Han; Sun,Yu; Gao,Weicun; Li,Bo; Dong,Xiaolin; Zhang,Yandong; Xia,Zhiping

doi:10.3892/etm.2017.5277

Effectiveness of C5a aptamers in a TNBS‑induced colitis mouse model

Authors:
- Zhiping Li
- Xiwen Wang
- Man Chen
- Yuanyuan Wang
- Rui Sun
- Han Qu
- Yu Sun
- Weicun Gao
- Bo Li
- Xiaolin Dong
- Yandong Zhang
- Zhiping Xia
View Affiliations

Affiliations: Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Institute, Academy of Military Medical Sciences, Changchun, Jilin 130000, P.R. China, Department of Rheumatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: October 10, 2017 https://doi.org/10.3892/etm.2017.5277
Pages: 6119-6124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The complement-activated product, complement component 5a (C5a), is a potent inflammatory peptide with a broad spectrum of functions. In vivo and in vitro studies have demonstrated that C5a serves an important role in inflammation; however, the role of C5a in the pathogenesis of inflammatory bowel disease (IBD) is not known. The purpose of the current study was to investigate the role of C5a in IBD using an experimental mouse model of colitis. Colitis was induced in mice using 2,4,6-trinitrobenzene sulfonic acid (TNBS), and C5a aptamers were subsequently administered via intraperitoneal injection. Clinical symptoms of the disease, histopathological analysis of the colon and the level of inflammatory components were examined. The symptoms of colitis, including changes in behavior, weight loss, colon damage and an increase in inflammatory cytokines, were attenuated following the treatment of mice with TNBS‑induced colitis with C5a aptamers. The aptamer‑treated mice exhibited a marked attenuation of colitis when compared with untreated mice, as demonstrated by the phenotypic observations, histological examinations and inflammatory cytokine levels. Colitis is characterized by an imbalance between pro‑inflammatory and anti‑inflammatory mediators. The results of the current study suggest that C5a may serve a critical role in inflammation in IBD.

View Figures

View References

1	Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–434. 2007. View Article : Google Scholar : PubMed/NCBI
2	Sartor RB: Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol. 92 12 Suppl:5S–11S. 1997.PubMed/NCBI
3	Saeed SA and Kugathasan S: Epidemiology of pediatric inflammatory bowel disease. Pediatr Inflam Bowel Dis. 71–86. 2017.
4	Singh UP, Singh NP, Busbee B, Guan H, Singh B, Price RL, Taub DD, Mishra MK, Nagarkatti M and Nagarkatti PS: Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol. 31:66–84. 2012. View Article : Google Scholar : PubMed/NCBI
5	Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, et al: A second serine protease associated with mannan-binding lectin that activates complement. Nature. 386:506–510. 1997. View Article : Google Scholar : PubMed/NCBI
6	Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G and Lambris JD: Complement therapeutics in inflammatory diseases: Promising drug candidates for C3-targeted intervention. Mol Oral Microbiol. 31:3–17. 2016. View Article : Google Scholar : PubMed/NCBI
7	Guo RF and Ward PA: Role of C5a in inflammatory responses. Annu Rev Immunol. 23:821–852. 2005. View Article : Google Scholar : PubMed/NCBI
8	Czermak BJ, Sarma V, Bless NM, Schmal H, Friedl HP and Ward PA: In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha. J Immunol. 162:2321–2325. 1999.PubMed/NCBI
9	Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegård KT, Köhl J and Lambris JD: Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 100:1869–1877. 2002.PubMed/NCBI
10	Dang L, He L, Wang Y, Xiong J, Bai B and Li Y: Role of the complement anaphylatoxin C5a-receptor pathway in atopic dermatitis in mice. Mol Med Rep. 11:4183–4189. 2015. View Article : Google Scholar : PubMed/NCBI
11	Bamberg CE, Mackay CR, Hyun L, Zahra D, Jackson J, Lim YS, Whitfeld PL, Craig S, Corsini E, Lu B, Gerard C and Gerard NP: The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem. 285:7633–7644. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Rollins SA, Madri JA and Matis LA: Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA. 92:pp. 8955–8959. 1995, View Article : Google Scholar : PubMed/NCBI
13	Makrides SC: Therapeutic inhibition of the complement system. Pharmacol Rev. 50:59–87. 1998.PubMed/NCBI
14	Kaur G and Roy I: Therapeutic applications of aptamers. Expert Opin Investig Drugs. 17:43–60. 2008. View Article : Google Scholar : PubMed/NCBI
15	Parashar A: Aptamers in therapeutics. J Clin Diagn Res. 10:BE01–BE06. 2016.PubMed/NCBI
16	Jain U, Otley AR, Van Limbergen J and Stadnyk AW: The complement system in inflammatory bowel disease. Inflamm Bowel Dis. 20:1628–1637. 2014. View Article : Google Scholar : PubMed/NCBI
17	Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, McLeod RS, Griffiths AM, Green T, Brettin TS, Stone V, Bull SB, et al: Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet. 66:1863–1870. 2000. View Article : Google Scholar : PubMed/NCBI
18	Speidl WS: Atherosclerosis and complement: Anaphylatoxin C5a as a new risk marker and therapeutic target. Clin Lipidol. 6:123–126. 2011. View Article : Google Scholar
19	Holers VM: Complement and its receptors: New insights into human disease. Annu Rev Immunol. 32:433–859. 2014. View Article : Google Scholar : PubMed/NCBI
20	Gasque P: Complement: A unique innate immune sensor for danger signals. Mol Immunol. 41:1089–1098. 2004. View Article : Google Scholar : PubMed/NCBI
21	Dempsey PW, Allison ME, Akkaraju S, Goodnow CC and Fearon DT: C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science. 271:348–350. 1996. View Article : Google Scholar : PubMed/NCBI
22	Ogden CA and Elkon KB: Role of complement and other innate immune mechanisms in the removal of apoptotic cells. Curr Dir Autoimmun. 9:120–142. 2006.PubMed/NCBI
23	Woodruff TM, Ager RR, Tenner AJ, Noakes PG and Taylor SM: The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med. 12:179–192. 2010. View Article : Google Scholar : PubMed/NCBI
24	Guo RF, Riedemann NC and Ward PA: Role of C5a-C5aR interaction in sepsis. Shock. 21:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
25	Lee T, Lee E, Irwin R, Lucas PC, McCabe LR and Parameswaran N: β-Arrestin-1 deficiency protects mice from experimental colitis. Am J Pathol. 182:1114–1123. 2013. View Article : Google Scholar : PubMed/NCBI
26	Margonis GA, Christoloukas N, Antoniou E, Arkadopoulos N, Theodoropoulos G, Agrogiannis G, Pikoulis E, Patsouris ES, Zografos GC and Papalois AE: Effectiveness of sildenafil and U-74389G in a rat model of colitis. J Surg Res. 193:667. 2015. View Article : Google Scholar : PubMed/NCBI
27	Afif W and Loftus EV Jr: Safety profile of IBD therapeutics: Infectious risks. Gastroenterol Clin North Am. 38:691–709. 2009. View Article : Google Scholar : PubMed/NCBI
28	Keefe AD, Pai S and Ellington A: Aptamers as therapeutics. Nat Rev Drug Discov. 9:537–550. 2010. View Article : Google Scholar : PubMed/NCBI
29	Hermann T and Patel DJ: Adaptive recognition by nucleic acid aptamers. Science. 287:820–825. 2000. View Article : Google Scholar : PubMed/NCBI
30	Nimjee SM, Rusconi CP and Sullenger BA: Aptamers: An emerging class of therapeutics. Annu Rev Med. 56:555–583. 2005. View Article : Google Scholar : PubMed/NCBI
31	Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, et al: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 112:1747–1757. 2005. View Article : Google Scholar : PubMed/NCBI
32	Bunka DH, Platonova O and Stockley PG: Development of aptamer therapeutics. Curr Opin Pharmacol. 10:557–562. 2010. View Article : Google Scholar : PubMed/NCBI
33	Dobrovolsky AB, Titaeva EV, Khaspekova SG, Spiridonova VA, Kopylov AM and Mazurov AV: Inhibition of thrombin activity with DNA-aptamers. Bull Exp Biol Med. 148:33–36. 2009. View Article : Google Scholar : PubMed/NCBI
34	Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D and Sullenger BA: RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 419:90–94. 2002. View Article : Google Scholar : PubMed/NCBI
35	Kubik MF, Bell C, Fitzwater T, Watson SR and Tasset DM: Isolation and characterization of 2′-fluoro-, 2′-amino-, and 2′-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding. J Immunol. 159:259–267. 1997.PubMed/NCBI
36	Li N, Nguyen HH, Byrom M and Ellington AD: Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One. 6:e202992011. View Article : Google Scholar : PubMed/NCBI